
    
      This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to
      evaluate the safety and efficacy of leronlimab (PRO 140) in patients with prolonged symptoms
      caused by COVID-19. Patients will be randomized to receive weekly doses of 700 mg leronlimab
      (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous
      injection.

      The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
      Total study duration is 91 days. The study will be conducted at up to 5 centers in the United
      States and planned number of subjects are 50 subjects.
    
  